hiPSC-CM therapy for heart failure

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 29 Jul 2021: Trial registered, NCT04982081
  2. 21 Sep 2021: Trial started, NCT04982081
  3. 4 Feb 2022: Trial registered, NCT05223894
  4. 30 Jun 2022: Trial started, NCT05223894

The trials

NCT04982081: Treating Congestive HF With hiPSC-CMs Through Endocardial Injection

State
State not given
Phase
Phase 1
People
20 planned
Started
21 Sep 2021
Primary completion
30 Dec 2022
Arms
hiPSC-CM therapy low dosage, hiPSC-CM therapy high dosage
Results
None posted
  1. 29 Jul 2021: Trial registered
  2. 21 Sep 2021: Trial started

NCT05223894: Treating Heart Failure With hiPSC-CMs

State
State not given
Phase
Phase 1 and Phase 2
People
20 planned
Started
30 Jun 2022
Primary completion
30 Dec 2025
Arms
hiPSC-CM therapy
Results
None posted
  1. 4 Feb 2022: Trial registered
  2. 30 Jun 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.